DIAMYD MEDICAL AB (DMYD.B)

Overview

Diamyd Medical AB (publ) is dedicated to the development of precision medicine therapies aimed at autoimmune diabetes treatment. Originally starting operations in 1984 and undergoing a name change from Diamyd Therapeutics AB to Diamyd Medical AB (publ) in April 2013, the company has established its headquarters in Stockholm, Sweden. Through its advanced clinical trials and strategic partnership with organizations like the Juvenile Diabetes Research Foundation, Diamyd Medical is at the forefront of pioneering treatments targeted at type 1 diabetes and latent autoimmune diabetes in adults (LADA). This commitment to innovation not only underscores its role in medical research but also highlights its potential in changing the lives of patients with autoimmune diabetes through novel therapies.

Products and Services

• Diamyd

An antigen-specific immunotherapy currently in phase III clinical trial, Diamyd is being developed by Diamyd Medical for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA). This promising therapy leverages the body's own immune system, aiming to stop the autoimmune process that destroys pancreatic beta cells in patients suffering from these types of diabetes. The hope is that Diamyd will provide a targeted approach that could potentially halt or significantly delay the progression of the disease, offering a new lease on life for those affected.

• Remygen

Remygen represents Diamyd Medical's foray into immunomodulation therapy, now in a phase I/II clinical trial. Targeting a broader range of diabetes types, including type 1 diabetes, type 2 diabetes, and LADA, Remygen seeks to renew insulin production by regenerating beta cells in the pancreas or protecting the existing ones. This approach could revolutionize current diabetes treatments by not just managing symptoms but by addressing one of the underlying causes of the disease. The clinical trials are a critical step in determining the efficacy and safety of Remygen for a vast array of patients, potentially making it a cornerstone therapy in diabetes care.